Pfizer COVID-19 vaccine set to generate sales of $30 billion
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
List view / Grid view
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.
Richard Daniell explains why Europe needs a strong pharmaceutical manufacturing base and supply chain to ensure a resilient network.
The trial will assess the safety and immunogenicity of a single intranasal dose of COVI-VAC in 48 healthy volunteers in the UK.
The EMA has received a conditional marketing authorisation application for the Oxford-AstraZeneca COVID-19 vaccine.
The agreement is expected to advance the commercial-scale manufacturing of the NVX-CoV2373 to enable it to be distributed across Europe following regulatory approval.
The international Phase III trial will evaluate whether a 14 day course of carrimycin can improve outcomes for COVID-19 patients with severe symptoms.
The FDA has alerted clinical laboratory staff and healthcare providers that it is monitoring the potential impact of SARS-CoV-2 mutations, including the UK variant.
Research shows that the antibodies induced by the Pfizer-BioNTech COVID-19 vaccine can neutralise SARS-CoV-2 viruses with the N501Y mutation.
The MHRA has given the green light to the Moderna COVID-19 vaccine for use in the UK, making it the third to be approved in the country.
AM-Pharma has announced the enrolment and financing of a COVID-19 cohort in its Phase III acute kidney injury treatment trial.
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
Moderna's COVID-19 vaccine has been approved in the EU with a conditional marketing authorisation by the European Commission.
Marta Kalas explains how to develop a COVID Safety Toolkit to ensure pharmaceutical businesses comply with changing regulations.